472 related articles for article (PubMed ID: 35845296)
1. Understanding the cellular interactome of non-alcoholic fatty liver disease.
Wallace SJ; Tacke F; Schwabe RF; Henderson NC
JHEP Rep; 2022 Aug; 4(8):100524. PubMed ID: 35845296
[TBL] [Abstract][Full Text] [Related]
2. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
4. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
5. Cooperation of liver cells in health and disease.
Kmieć Z
Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
[TBL] [Abstract][Full Text] [Related]
6. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
7. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
9. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases.
Campisano S; La Colla A; Echarte SM; Chisari AN
Nutr Res Rev; 2019 Jun; 32(1):128-145. PubMed ID: 30707092
[TBL] [Abstract][Full Text] [Related]
10. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
11. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Tacke F; Puengel T; Loomba R; Friedman SL
J Hepatol; 2023 Aug; 79(2):552-566. PubMed ID: 37061196
[TBL] [Abstract][Full Text] [Related]
12. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease.
Meijnikman AS; Herrema H; Scheithauer TPM; Kroon J; Nieuwdorp M; Groen AK
JHEP Rep; 2021 Aug; 3(4):100301. PubMed ID: 34113839
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.
Kumar S; Duan Q; Wu R; Harris EN; Su Q
Adv Drug Deliv Rev; 2021 Sep; 176():113869. PubMed ID: 34280515
[TBL] [Abstract][Full Text] [Related]
14. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
15. Treating inflammation to combat non-alcoholic fatty liver disease.
Wiering L; Tacke F
J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
[TBL] [Abstract][Full Text] [Related]
16. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells.
Kiagiadaki F; Kampa M; Voumvouraki A; Castanas E; Kouroumalis E; Notas G
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):891-899. PubMed ID: 29287776
[TBL] [Abstract][Full Text] [Related]
17. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
[TBL] [Abstract][Full Text] [Related]
18. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men.
Zimny S; Pohl R; Rein-Fischboeck L; Haberl EM; Krautbauer S; Weiss TS; Buechler C
Exp Mol Pathol; 2017 Aug; 103(1):1-8. PubMed ID: 28600126
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH).
Rajak S
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167102. PubMed ID: 38422712
[TBL] [Abstract][Full Text] [Related]
20. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
